Achillion Pharmaceuticals (Achillion Pharmaceuticals) Total Assets : $236.34 Mil (As of Sep. 2019)

View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals Total Assets?

Achillion Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2019 was $236.34 Mil.

Total Assets is connected with ROA %. Achillion Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2019 was -32.32%. Total Assets is also linked to Revenue through Asset Turnover. Achillion Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2019 was 0.00.

Achillion Pharmaceuticals Total Assets Historical Data

The historical data trend for Achillion Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals Total Assets Chart

Achillion Pharmaceuticals Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Assets

Get a 7-Day Free Trial

156.81

464.53

413.88

337.61

277.86

Achillion Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Assets	Get a 7-Day Free Trial															289.18	277.86	262.68	248.38	236.34

Achillion Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Achillion Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2018 is calculated as

Total Assets	=	Total Equity (A: Dec. 2018 )	+	Total Liabilities (A: Dec. 2018 )
	=	266.012	+	11.846
	=	277.86

Achillion Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2019 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2019 )	+	Total Liabilities (Q: Sep. 2019 )
	=	217.216	+	19.126
	=	236.34

Achillion Pharmaceuticals (NAS:ACHN) Total Assets Explanation

Total Assets is connected with ROA %.

Achillion Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2019 is

ROA %	=	Net Income (Q: Sep. 2019 )	/	( (Total Assets (Q: Jun. 2019 )	+	Total Assets (Q: Sep. 2019 ))	/ count )
	=	-78.332	/	( (248.375	+	236.342)	/ 2 )
	=	-78.332	/	242.3585
	=	-32.32 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Achillion Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2019 is

	Asset Turnover
=	Revenue (Q: Sep. 2019 )	/	( (Total Assets (Q: Jun. 2019 )	+	Total Assets (Q: Sep. 2019 ))	/ count )
=	0	/	( (248.375	+	236.342)	/ 2 )
=	0	/	242.3585
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Achillion Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 George Street, New Haven, CT, USA, 06511

Website

http://www.achillion.com

Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.

Executives

Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves	director	C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman	director	C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo	director	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning	officer: General Counsel	700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta	officer: EVP, Chief Commercial Officer	550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske	officer: EVP, Chief Medical Officer	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton	officer: Chief Financial Officer	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande	director, officer: Chief Executive Officer	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian	officer: Chief Medical Officer	C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511